11 articles
A myeloma trial has already read out, and two bigger oncology dates follow: ESMO on Oct. 24 and an FDA decision on Nov. 14. We checked Merck's SEC-filed numbers alongside the dated company statements, and we flag where the source material is weaker.
Two dated events frame oncology's near term: detailed intismeran data at ESMO on Oct 24 and a Nov 14 FDA decision date for Summit's ivonescimab. SEC-checked Merck figures show cash down and costs up. The AI-in-discovery story rests on a source where none of 11 checked claims held up.
A personalized Merck/Moderna melanoma vaccine, record Novocure revenue and an ivonescimab FDA date headline a bullish oncology week. SEC-checked Merck filings show cash down from $14.6B to $6.8B in two quarters, and the AI-biologics evidence is the weakest link.
Brad Lightcap, OpenAI's former chief operating officer who had shifted into a special-projects role, is departing the company.
NVIDIA's Hopper 300 and Blackwell GPU architectures power expanding enterprise AI deployment across medical imaging and autonomous systems. Stanford research shows 20%+ performance gains from human video training data, but emerging Kolmogorov-Arnold Network tests reveal neural architecture struggles with multiplicative physics problems.
Microsoft has captured 900 million monthly AI users and 90% of Fortune 500 companies with its Copilot platform, but persistent capacity constraints through fiscal year-end reveal infrastructure struggles to meet surging enterprise demand. The gap has triggered a industry-wide scramble as legacy software vendors and non-tech firms pivot to AI capabilities while regional players pursue alternative strategies like quantum computing research.
A wave of experimental immunotherapy platforms is approaching commercialization as AstraZeneca, Syndax, Eledon, and OS Therapies advance novel treatments through late-stage trials and regulatory reviews. The companies are targeting cancers and conditions that have historically resisted treatment, with multiple therapies expected to reach patients in 2026.
A concentrated wave of positive clinical trial results has emerged across four therapeutic areas in early 2026, with multiple drug candidates meeting primary endpoints simultaneously. The convergence of success in multiple sclerosis, lupus, heart rhythm disorders, and blood cancer treatments reflects a maturing cycle of pharmaceutical development that could reshape treatment options within two years.
Pharmaceutical giants are aggressively consolidating oncology assets through strategic acquisitions and breakthrough regulatory approvals, signaling a fundamental shift in how the industry approaches cancer treatment development. Johnson & Johnson's recent acquisitions of Shockwave Medical and Halda Therapeutics, combined with FDA approvals for advanced combination therapies, reflect a broader industry trend toward concentrating next-generation cancer platforms within established pharmaceutical
NVIDIA is positioning itself as the dominant infrastructure provider for AI-driven pharmaceutical research through its BioNeMo platform, securing partnerships with major players including Thermo Fisher and Eli Lilly. The move represents a strategic expansion beyond traditional computing applications into the life sciences sector, where AI-native biotech firms are increasingly relying on specialized hardware for drug discovery.
Broadcom has secured more than $21 billion in custom AI accelerator orders from hyperscale cloud providers, marking a strategic transformation from its traditional semiconductor and enterprise software roots into a essential supplier for the artificial intelligence infrastructure race. The orders, including commitments from Anthropic and at least four other major customers, position the company at the center of the industry's massive datacenter expansion.